Osteoporosis drug delisted from PBS

Strontium ranelate (Protos) has been delisted from the PBS, with patients expected to pay up to $60 for a private prescription.  

The drug has been mired in controversy since 2014 when a European Medicines Agency sub-committee concluded strontium’s risk-benefit profile was “no longer favourable” and that it should not be used to treat osteoporosis.

However, the drug has now finally been delisted, and there are no generics or alternative formulations available for patients.

Pharmacist and NPS MedicineWise advisor Aine Heany says the delisting is a good reminder to re-evaluate the costs and benefits of strontium.

“It’s an opportunity to think about their treatment and

Latest

Trending